First Interchangeable Humira Biosimilar Approved In US
Boehringer Ingelheim’s Cyltezo Adalimumab Rival Is Granted Second Ever FDA Designation
Boehringer Ingelheim has won a landmark first US interchangeability designation for a biosimilar to Humira, with the firm’s Cyltezo version of adalimumab representing the second ever interchangeable biosimilar approved by the FDA.
